Influenza Vaccine Compr

Influenza Vaccination, ACEI and ARB in the Evolution of COVID-19

A study to determine if influenza vaccination or ACEI or ARB medication has effects on COVID-19


Have you had COVID-19? Are you vaccinated against the influenza, or taking ACEI or ARB medication? Contact the PI by clicking the button below.

What do you know about ACEI and ARB?

Angiotensin-converting-enzyme inhibitors (ACEI) and Angiotensin II Receptor blockers (ARB) are medicines to lower blood pressure and for the treatment of heart failure.

Description of the Study:

  • Title: Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-Covid19 Infection.
  • Principal Investigator: Anna Puigdellívol-Sánchez.
  • Center of Implementation: Consorci Sanitari de Terrassa.
  • Study Population: 2574 patients admitted in the Hospital of Terrassa from March 1, 2020, with any of the following conditions: COVID-19, Influenza Vaccination, ACE inhibitor or Angiotensin II receptor antagonist.
  • Study Type: Observational study.
  • Design:
    – If patients treated with ACE inhibitor evolve positively, this treatment would be added in a random selection of new admitted patients suffering COVID-19, and results would be compared to a control group of admitted patients.
    – If patients treated with ARB evolve positively, this treatment would be added in a random selection of new admitted patients suffering COVID-19, and results would be compared to a control group of admitted patients.

Objectives of the Study:

Principal Objective: The primary objective is to evaluate whether the admitted patients who have previously received the influenza vaccine or treated with ACEI or ARB show a better evolution.
To study the number of patients admitted at the hospital, their comorbidity (Charlson index), the number of previous treatments, the length of admission, the need or not of the Intensive Care Unit (ICU) and their final status (survivors or non survivors).

More about this Study:

Scientific Context: Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection.

The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving treatment show a better evolution.

Consorci Sanitari de Terrassa: The CST is an integrated healthcare organisation with a public service vocation, which is a consortium of the Autonomous Government of Catalonia, Terrassa City Council and the San Lázaro Foundation.

The CST centres have more than 2,000 professionals who provide highly qualified health and social care to a reference population of more than 160,000 inhabitants.

Cst
Jordi Gol I Gurina Foundation
Iec

Other Studies about Pharmacology:

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.

CIBERESUCI COVID

CIBERES UCI COVID is a fundamental study that will improve care of critical patients infected by COVID-19.

Vaccination In People With Long COVID

This study aims to determine the effects of vaccination against SARS-CoV-2 in people with long COVID.

ANTICOV Study: COVID-19 in Africa

Collaborate with ANTICOV study to treat COVID-19 in Africa.

Antibiotic prescription during the COVID-19 pandemic

Antimicrobial stewardship approaches urgently need to be reinforced during the COVID-19 pandemic. This study evaluates the impact of the COVID-19 on antibiotic consumption.

Antihistamines and azithromycin as a treatment for COVID-19

This study suggests that primary care diagnosis and treatment with antihistamines, plus azithromycin in selected cases, may treat COVID-19 and prevent progression to severe disease…

Immunomodulatory Treatment In Patients With Severe Pneumonia COVID-19

Clinical trial to perform immunomodulatory treatment in adult patients with severe COVID-19 pneumonia with the aim of helping to define the standard treatment for this…

Real-life Use Of Remdesivir In Hospitalized Patients With COVID-19

This study aims to evaluate in clinical practice the efficacy and safety of remdesivir in patients admitted for COVID-19.

Prevention With Calcifediol Of Respiratory Problems Caused By COVID-19

This multicentre clinical trial aims to demonstrate that treatment with Calcifediol reduces the need for invasive ventilation and Intensive Care Unit admissions and deaths.

Maraviroc in patients hospitalized for COVID-19

Phase II clinical trial evaluating the safety and efficacy of the drug Maraviroc combined with standard therapy versus standard therapy in patients infected with SARS-CoV-2…